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Abstract
Background: Whiplash associated disorder is commonly linked to motor vehicle accidents and
sports injuries. Cervical injury is attributed to rapid extension followed by neck flexion. The exact
pathophysiology of whiplash is uncertain but probably involves some degree of aberrant muscle
spasms and may produce a wide range of symptoms. The most commonly prescribed
pharmacological agents for initial treatment of whiplash-associated pain are oral muscle relaxants
and nonsteroidal anti-inflammatory drugs. However, potential systemic adverse effects limit these
agents. Physical interventions such as mobilization, manipulation, and exercises have proved
beneficial for pain and dysfunction but only on a time-limited basis. Little evidence suggests that
physical therapy specifically aimed at the musculature (e.g., transcutaneous electrical nerve
stimulation, ultrasonography, heat, ice, and acupuncture) improves prognosis in acute whiplash
associated disorder. A new approach to treatment is the use of botulinum toxin, which acts to
reduce muscle spasms.
Methods/design: This is a prospective, randomized, controlled clinical trial and botulinum toxin-
A (Botox®) injections will be compared with placebo injections. The primary objective is to
determine the efficacy of Botox® in the management of musculoskeletal pain in whiplash associated
disorders.
Discussion: Botulinum toxin type-A toxin has been studied in small trials on whiplash associated
disorder patients and has generally been found to relieve pain and improve range of motion.
Specifically, we seek to assess the efficacy of Botox® in reducing pain and to improve the cervical
spine range of movement, during the 6-month trial period.
Background
The term "whiplash" has been used to describe a mecha-
nism of injury, and the various clinical manifestations as
a consequence of the injury. Moreover, signs and symp-
toms have been designated the 'whiplash syndrome'. In
1995, the Quebec Task Force (QTF) on Whiplash Associ-
ated Disorders (WAD) adopted the following definition
of whiplash: "whiplash is an acceleration-deceleration
mechanism of energy transfer to the neck. It may result
from rear-end or side-impact motor vehicle collisions, but
can also occur during diving or other mishaps. The impact
may result in bony or soft-tissue injuries (whiplash-
injury), which in turn may lead to a variety of clinical
manifestations called Whiplash Associated Disorders"[1].
Whiplash patients can be classified according to severity
of signs and symptoms. The QTF-WAD classification sys-
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tem consists of five levels: WAD 0 indicates no complaints
or physical signs; WAD I indicates neck complaints but no
physical signs; WAD II indicates neck complaints and
musculoskeletal signs (such as a decreased range of
motion or muscle tenderness); WAD III and IV indicate
neck complaints and neurological signs (WAD III) or frac-
ture/dislocation (WAD IV), respectively. Research [2-5]
has revealed that the most common presenting symptoms
following an acute motor vehicle collision were neck pain
(88–100 percent) and headache (54–66 percent). Other
symptoms were neck stiffness, shoulder pain, arm pain/
numbness, paraesthesia, weakness, dysphagia, visual and
auditory symptoms and dizziness.
The incidence of whiplash injury varies greatly through-
out the world with rates between 70–200 per 100,000
inhabitants [1,6]. There is no consensus about the natural
course of the whiplash injuries [7,8]. These authors con-
cluded that between 14 and 42 percent of the whiplash
patients developed chronic complaints (over six month
duration), and that 10 percent of those patients had con-
stant severe pain.
In most cases, WAD resolves quickly; 47% of injured peo-
ple returns to normal activities within 4 weeks and only
2% continue to be absent from pre-accident activities 1
year after injury [1]. WAD is considered chronic if pre-
accident activity levels are not gained within 6 months.
Ongoing cervical pain and reduced range of motion
(ROM) associated with chronic WAD constitute both a
prognostic and a therapeutic dilemma. Researchers have
argued about whether chronic WAD even exists, suggest-
ing that it might be a function of social conditioning, psy-
chological makeup, and/or medico-legal compensation
[9-14]. Despite this uncertainty, chronic neck pain does
exist, and it can be initiated or perpetuated by an event
such as a whiplash injury. The location and severity of tis-
sue injury and the prognosis of chronic neck pain may
depend on predisposing neck pathology. In addition to
peripheral input, long-standing neck pain (like other
chronic pain conditions) may be associated with a central
component that can modify the pain threshold [15]. Con-
siderable research has been dedicated to determine of the
direct and indirect roles of the zygapophyseal joints in the
generation of pain and dysfunction in whiplash injury
[16]. Blocking the sensory nerves that innervate these
joints reduced symptoms in 50% of the subjects with
chronic whiplash pain [17]. However, this finding sug-
gests that no responders might have been suffering from a
pathology related not to the joints but to soft tissue.
Almost nine of 10 whiplash sufferers had some degree of
muscle spasm [18]. This aberrant muscle activity is further
supported by use of surface electromyography (SEMG) in
patients with whiplash revealed cervical muscle dysfunc-
tion [19]. In particular, these patients had decreased abil-
ity to relax the trapezius muscles. Such a finding raises the
question of whether cervical muscular dysfunction causes
ongoing excess loading of the zygapophyseal joints, yield-
ing the clinical picture of chronic whiplash, or whether
muscle dysfunction is an attempt by the body to splint a
subtly injured cervical spine.
The most commonly prescribed pharmacological agents
for initial treatment of whiplash-associated pain are oral
muscle relaxants and nonsteroidal anti-inflammatory
drugs [20,21]. However, the effectiveness of these drugs in
some patients is limited by their systemic therapeutic
effect and unfavourable side effects. Physical interven-
tions such as mobilization, manipulation, and exercises
have proved beneficial for pain and dysfunction but only
on a time-limited basis. Little evidence suggests that phys-
ical therapy specifically aimed at the musculature (e.g.,
transcutaneous electrical nerve stimulation, ultrasonogra-
phy, heat, ice, and acupuncture) improves prognosis in
acute WAD [8]. In chronic WAD, the only treatment that
has clearly shown benefit is radiofrequency neurotomy
[22]. Because only 49% of patients with whiplash have
symptomatology related to cervical zygapophyseal joint
pain, the remainder requires an alternate therapy [17].
The use of botulinum toxin (BTX) for the treatment of
muscle pain in WAD has not been extensively studied or
reported. This is also the case for chronic neck pain unas-
sociated with a whiplash injury. Recently, a study explor-
ing the potential benefits of relaxing selected neck muscles
with botulinum toxin type-A (BTX-A) has been published
[23]. In this randomized, placebo controlled trial, 28 sub-
jects with chronic grade II WAD received injections of 100
units (U) of BTX-A or saline placebo. Each subject received
bilaterally five injections of 0.2 ml each into one or more
of the following sites: splenius capitis, rectus capitis, sem-
ispinalis capitis, and trapezius. The five injection sites
were chosen by palpation and corresponded to the five
tenderest cervical muscular points. BTX-A was injected
using a 30-gauge needle without electromyography
(EMG) guidance. Follow-up assessments were carried out
at 2 and 4 weeks after injection. Three outcome measures
were considered: subjective pain, objective ROM in the
neck, and subjective function. Subjective pain assessment
was based on visual analogical scale (VAS) for neck pain,
headache, and shoulder pain. At week 4 after injection,
this group had significantly improved from pre-injection
levels (P < 0.01). The placebo group did not demonstrate
any significant changes at any time after treatment. This
study is small and of short duration, but the results sug-
gest that relaxing the cervical musculature is important in
relieving pain and improving ROM in patients with WAD
[24]. I have reported a significant reduction in pain as well
as an improvement in ROM in 77.4% of patients respond-
ing significantly to a BTX-A injection in an open labelBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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study with 31 patients grade II WAD. Patients received
50–75 units of BTX-A, and the follow-up assessment was
at week 8 [25]. BTX-A, specifically Botox®, has been stud-
ied for the treatment of WAD and chronic neck pain. BTX
type-B has been studied in patients with post-whiplash
headaches [26].
Methods/Design
This is a randomized, prospective, double blind, placebo-
controlled trial comparing BTX-A (Botox®) with placebo.
The study evaluates the efficacy and safety of Botox® in
patients with musculoskeletal pain after whiplash associ-
ated disorders. The study will be conducted following all
applicable institutional review board requirements and
the subjects will provide written, informed consent before
enrolment.
The trial will be at Whiplash Clinic in Povisa Medical
Center, a tertiary referral center that sees approximately
800 patients per year with whiplash associated disorders.
Patients will be referred from departmental and institu-
tional colleagues as well as from regionally traffic accident
insurances physicians.
Randomization
Patients eligible for inclusion will be randomized, and the
study treatment started. Participants will be randomized
by a computer-generated randomisation scheme and the
clinical investigators evaluating each subject during the
follow-up assessment will be blinded. The study compu-
ter will then randomly assign a treatment pack number
that will identify one of the treatment packs stored in the
department. Group A will receive treatment with Botox®
and Group B will receive treatment with placebo injec-
tions. Documentation of treatment injection sites and vol-
ume injected will be recorded in the treatment procedure
forms.
The treatment allocation schedule will be stored by the
site's pharmacy. Study drug will be prepared by the phar-
macy at each site. The study drug packages will be labeled
with the identification number from the treatment alloca-
tion schedule.
Blinding
Both the patient and principal investigator and his staff
will be blinded as to the identity of the randomized study
medication. Blinding will be maintained by having a des-
ignated pharmacist (the only person to have access to the
randomization list) providing the principal investigator
or study coordinator with a vial containing the study med-
ication labeled with the patient's sequential identification
number from the randomized allocation schedule. All
patients will remain double blind until after the last
patient has completed the study. Patients in each group
will complete an 6-month follow-up.
Inclusion criteria
• Patients with grade II WAD of QTF-WAD
• Neck pain secondary to cervical whiplash injury with
muscoskeletal signs* of >3 months.
• >18 years.
• Lack of response to conventional physical and medical
therapy
*Muscoskeletal signs
• Palpable band, spot tenderness, and jump sign in cervi-
cal muscles or restricted range of motion in cervical spine.
• Demonstrated precipitation of neck pain with external
pressure over the occipital or cervical region on affected
side.
• Myofascial pain of cervical muscles.
• Experienced pain on maneuver of stretching,
• Trigger point with associated referred pain.
Exclusion criteria
• Serious somatic or psychiatric illness
• Anticoagulation therapy
• Myasthenia gravis
• Pregnancy or breast-feeding
• Abnormal anatomy
• Rheumatoid disease or radiculopathy, need for regular
analgesic for severe pain
• Fixed contracture
Patient Screening
Prospective patients will be subjected to a preliminary
examination, which will include general medical history,
and complete physical and neurological examination.
Those meeting the provisional eligibility requirements of
the study will be asked to sign the Patient Consent Form.
All patients who are given the screening examination will
have their name entered into a Screening/Enrollment log
along with the date and time of examination. If theBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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patient is ineligible for participation, an explanatory note
will be provided in the Screening/Enrolment Log. Rand-
omization numbers will only be assigned to patients who
are fully eligible, and agree to participate in the study.
Study treatment
• Botox® (Botulinum Toxin Type-A, Allergan, Inc., Irvine,
CA) is supplied as a sterile, preservative-free, vacuum
dried powder consisting of 100 units of Clostridium bot-
ulinum toxin, 0.5 mg human albumin, and 0.9 mg of
sodium chloride. Unpreserved sterile 0.9% saline solution
is used for resolubilization of the Botox® powder, and will
be used to prepare a 100 unit/ml Botox® solution.
Clinical use and safety of Botox®
We use Botox® and this protocol cannot be used to admin-
ister any other commercial preparation of BTX. Botox® is a
neurotoxin, is effective for treating a variety of disorders of
involuntary muscle contraction, including spasticity, cer-
vical dystonia, blepharospasm and hemifacial spasm. It
inhibits neuromuscular signaling by blocking the release
of acetylcholine at the neuromuscular junction. The bio-
logical effects of the toxin are transient with normal neu-
ronal signaling returning within approximately 3–6
months post injections. Botox® is available in a standard
vial that contains 100 units of toxin. The vacuum dried
toxin is reconstituted with 0.9 percent unpreserved sterile
saline to various concentrations just before usage,
depending on the indication. Preservatives in the saline
could inactive the toxin. The injection of the diluents into
the vial must be performed according to manufacturer's
recommendations with gentle mixing after allowing the
vacuum in the vial to draw in the injected diluents.
• Saline Solution: Unpreserved, sterile 0.9% saline solu-
tion will be obtained from the following commercial
source: B/Braun 10 ml sterile saline solution.
• Placebo: The placebo will consist of the saline solution
described in previous section.
Treatment
Up to a total of 1 ml of 0.9% saline (placebo treatment)
or active treatment (Botox®) will be injected; the following
muscles will be injected in all patients: splenius capitis,
semiespinalis, and trapezius. Each subject will receive five
injections of 0.2 ml (20 units) each into one or more of
the following sites: splenius capitis, semispinalis capitis,
and trapezius. The five injection sites will be chosen by
palpation and corresponded to the five tenderest cervical
muscular points. The number of injection sites per muscle
will be: trapezius three sites, semiespinalis one site, and
splenius one site. Maximum volume per site will be of 0.2
ml (20 units of 0.9% saline or active treatment). Total
maximum dose per treatment of Botox® will be of 100
units.
The concentration of this 0.9% saline solution reconsti-
tuted Botox® will be 100 units/ml, which means that the
amount of active treatment to be injected into the various
muscle groups will range from 20 to 60 units. The study
investigators will administer treatment using a combina-
tion of fixed injections sites and injection at sites of pain
or tenderness.
Injection technique
The injection technique used for the neck is based on
experience with cervical dystonia. The sites chosen are
chiefly in the large superficial muscles, specifically, the
splenius capitis, rectus capitis, semispinalis capitis, and
trapezius. These muscles can easily be palpated in most
individuals and can be injected without sophisticated
techniques. Most patients exhibit tender areas in the larger
muscles, often in conjunction with tight bands or knots.
These tender areas do not always meet the definition of
classic trigger points.
In our centre, Botox® is typically diluted to 10 U per 0.1 ml
of saline. In the large muscles of the neck and back, rela-
tively large volumes can be injected without diffusion to
adjacent structures. In the face or anterior neck, these
larger volumes are more likely to lead to unwanted paral-
ysis of neighbouring muscles [27]. The optimal dilutions
have not yet been determined.
During the injection technique, we do not use EMG guid-
ance or muscle stimulation.
To determine if the dose has been insufficient because of
excessive toxin distribution, large muscle bulk, or possibly
antibodies, providers can inject a small cosmetic dose into
the frontals muscle to verify the patient's response to the
toxin.
Adverse events
An adverse event is defined as any medical occurrence
whether or not related to treatment (including worsening
of a preexisting medical condition). They will be recorded
on the case report form provided for that purpose. If an
adverse event should occur, treatment will be provided by
the principal investigator or co-investigators, and follow-
up will continue until the event resolves. The principal or
co-investigators will also be responsible for characterizing
the nature and severity of the adverse event, its relation-
ship to the study medication (unrelated, uncertain, possi-
ble, and probable), any action taken to remedy the event,
and patient outcome. An adverse event that is serious, irre-
spective of its relationship to treatment, will be recorded
and reported appropriately.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
Page 5 of 10
(page number not for citation purposes)
Precautions
BTX-A treatment is potentially a painful procedure. It is
contraindicated in the presence of infection at the injec-
tion site(s) and in individuals with known hypersensitiv-
ity to any ingredient in the formulation.
Individuals with peripheral motor neuropathic diseases
or neuromuscular functional disorders should receive
BTX-A treatment with caution. BTX-A should also be used
with caution in patients receiving aminoglycosides or
other agents interfering with neuromuscular transmis-
sion.
Formation of neutralizing antibodies to BTX-A may
reduce its effectiveness by inactivating the biological activ-
ity of the toxin. The rate of formation of these neutralizing
antibodies in patients receiving BTX-A treatment has not
been well studied and the critical factors for neutralizing
antibody formation have not been well characterized. The
effect of the long-term use of BTX-A has not been studied,
however, the reformulated BTX-A has a lower protein con-
tent that may decrease the risk of antibody formation and
the development of resistance.
Study phases
There is a 6-month treatment and follow-up phase. There
will be a total of 12 clinic visits during the study period.
The first visit will be the patient's baseline evaluation, ran-
domization and treatment visit, and follow-up assess-
ment will be performed at 15 days intervals. Patients will
return to the Whiplash Clinic at 15 days, intervals, and all
assessment scales will be recorded at each follow-up visit.
At the final visit, a patient discontinuation form will be
completed for each patient. If a patient discontinues pre-
maturely, the outcome measures will be obtained at the
time of discontinuation.
Outcomes measures
Outcome measures include ROM, subjective pain and dis-
ability measure via VAS and Neck Pain Disability Index
(NDI). Objective tenderness to palpation will be recorded
using previous scales and systems.
Assessment
Objective assessment of treatment outcome of whiplash
can be difficult. Since 80 percent of patients responded in
the open-label trial, the success rate of the controlled
study should be downward adjusted by 20 percent. Com-
parison between studies is difficult, due to variations in
dosages, treatment protocols, evaluation methods, injec-
tion technique (single versus multiple sites), rating scales,
and definitions of improvements.
The following variables will be measured:
Subjective pain
Assessment using visual analogue scales (VAS) to assess
most severe pain and average pain intensity during the
study. VAS is a 10 cm pain intensity scale. In this numeri-
cal rating scale (0 = no pain, 10 = unbearable pain o the
worst pain experienced). The total score of three VAS
assessments will be reported.
Assessment of disability
Assessment of disability due neck pain with the NDI, a
modified version of the Oswestry Low Back Pain. [28].
Assessment of range of neck motion
We use CROM® Cervical Range of Motion Instrument,
with measurements of rotation, flexion, extension, and
lateral bending. Assessment of cervical Range of Motion
by CROM®: It is a magnetic inclinometer device. The
CROM® Cervical Range of Motion Instrument provides
accurate, repeatable measurements of cervical movement
and objective data that clinical studies required. The sys-
tem combines inclinometers and magnets to provide
accurate measurements of cervical range of motion in an
easy-to-use instrument. It eliminates positioning, zeroing
and tracking errors common with stand-alone inclinome-
ters. It allows rotation movements in upright position.
Standard protocol minimizes chance for examiner's
errors.
Assessment of health status
We use a generic measure of health status with the medi-
cal outcomes study 36-item short-form health survey
(SF36) [29].
Tenderness to palpation
Reaction to pressure will be graded from 0 to 3 with
respect to discomfort (0= no discomfort, 1=minimal,
2=moderate, 3= severe discomfort with minimal pres-
sure); this classification was used in previous studies.
In addition, we will use the Mechanical Algometer Pain
Test® from Wagner Instruments, USA. Many clinical appli-
cations of the Algometer have been documented, includ-
ing evaluation and identification of trigger points [30],
evaluation of pain sensitivity [31,32], Pressure measure-
ment has also been shown effective for evaluating the
results of pain relieving modalities such as anaesthetic
blocks, heat, manipulation, anti-inflammatory, as well as
documenting long-term treatment effectiveness [31,33].
Because of its reliability and reproducibility, algometry
can be used for objective medico-legal documentation of
pain intensity [34].
The methodology for assessment of palpation tenderness
using the Algometer Pain Test® is: a) Patient lie down,
exposing the areas to be tested. Supporting pillows shouldBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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be used to assist the patient in relaxing the muscles over-
lying the tender points. b) Explain the procedure to the
patient. Have the patient indicate the onset of pain with a
verbal cue such as "Yes" or "Stop", or by squeezing the
"Enter" footswitch. This adds another level of examiner
objectivity to the test. c) Use one of the standard test
points, or has the patient point to the specific area of dis-
comfort. Palpate with your fingertip to identify the point
of maximum sensitivity. Mark that point with a pen and
document its location with reference to an anatomical
landmark for future testing. d) Locate, mark, and docu-
ment the same point on the contralateral side if appropri-
ated. e) Use the appropriate tip for the area of the body
being tested. Typically, the 1.0 cm2  tip for torso and
extremities, and the 0.5 cm2 for the head and neck work
best. Denote the tip size in the dialog. f) Remind the
patient to stop the test upon the onset of pain, and place
the applicator tip over the mark. Apply force perpendicu-
lar to the skin's surface at a gradual rate of 2.2 pounds (1
kg) per second. Remove the Algometer when the patient
stops the test. Multiple readings may be taken to improve
reliability. g) Test the contralateral side if not a midline
test.
Pressure Tolerance Measurement: a) Have the patient lie
down, exposing the middle deltoid and the shin. b) Pal-
pate the bulk of the deltoid muscle to rule out the pres-
ence of local tenderness and/or pathology. Mark the point
of maximum muscle bulk with a pen. c) Explain the pro-
cedure to the patient. Have the patient indicate when the
pain becomes too great with a verbal cue or by squeezing
the "Enter" footswitch. d) Place the unit with the 1 cm2
applicator tip over the mark. Apply force perpendicular to
the skin's surface at a gradual rate of 2.2 pounds per sec-
ond. Remove the Algometer when the patient stops the
test. e) Multiple readings on the same site or contralateral
side may be performed to improve measurement reliabil-
ity. f) Repeat the procedure using the mid-tibia.
Surface electromyography
In order to find excessive electrical activity of muscles dur-
ing movement, hyperactivity after contraction and/or
inappropriate co-activation. SEMG activity of the upper
trapezius muscles is bipolar, recorded according the rec-
ommendations of SENIAM [35].
The amplitude of the SEMG using MYOMED® 932 (Enraf-
Nonius, Inc.) signals is usually expressed as some number
of microvolts, noted as series of relatively instantaneous
measurements, or averaged or integrated over a clinically
meaningful period. Amplitude analyses are conducted to
evaluate the magnitude and timing pattern of muscle
activity. Use of SEMG amplitudes has been described for
examination and feedback training in a wide variety of
musculoskeletal disorders [36,37]. Clinically less com-
mon than amplitude analyses, investigation in the fre-
quency domain is performed to study muscular fatigue.
SEMG amplitude, tracings, may be processed to, reveal a
range of component frequencies, the spectrum of which
shifts in a reliable way with fatigue [38]. That is, the fre-
quency spectrum becomes compressed toward slower val-
ues due to neuromuscular and metabolic changes
associated with high intensity isometric contractions. The
shift begins as the contractions are sustained beyond a
short time, preceding the actual loss of force, and contin-
ues as force declines. This way of fatigue monitoring may
have certain advantages over other measures [39] and suc-
cessfully discriminates spinal pain patients from control
subjects with impressive accuracy [40,41].
Several theories about musculoskeletal pain syndromes
such as WAD suggest that pain and muscle activity interact
and may contribute to the chronicity of symptoms. Stud-
ies using SEMG have demonstrated abnormal muscle acti-
vation patterns of the upper trapezius muscles in the
chronic stage of WAD (Grade II) [19]. The acute stage is
characterized by a reorganization of the muscular activa-
tion of neck and shoulder muscles, possibly aimed at min-
imizing the use of painful muscles [42]. Studies with
SEMG show excessive electrical activity of muscles during
movement, hyperactivity contraction, and/or inappropi-
ate coactivation with other muscles during movement.
The following protocol will be use in WAD using SEMG:
Skin adequately prepared, shaved and cleaned with 70%
alcohol. SEMG activity of the upper trapezius muscles
recorded bipolar, amplified using MYOMED® 932. Elec-
trode placements, according SENIAM. Patients seated in
upright position. Ag/AgCl pregelled electrodes with a cir-
cular diameter of 10 mm. Inter-electrode distance of ± 20
mm. The reference electrode over the spinous process of
C7, and electrode 2 cm laterally to the midpoint of the
line between the acromion and the spinous process of ver-
tebra C7. After electrode placement they are fixed to the
skin with tape. We recorded the muscle activity during
four stages:
• Baseline: Back supported, the hips and knees at 90° and
the hands resting in the lap.
• Reference electrical activation: while the arms are hold
straight and horizontally at 90° abduction in the frontal
plane of the body with the hand relaxed, and palms point-
ing downward.
• Physical exercises: The patient is asked to move his or
her dominant arm between three target areas by making
circles with a diameter of 70 mm using a pencil. Rest of
the non-dominant arm.BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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• Final or post-exercise: Immediately after exercise or
abduction of the arms we obtained the muscles activity.
According to Nederhand et al [19] we use the muscle acti-
vation patterns of upper trapezius: time related recovery
pattern, mean level of pre-exercise and mean level of post-
exercise. We record excessive electrical activity, inappro-
priate co-activation of others muscles during movement.
Sample size
Sample size calculation: Earlier studies have indicated that
it would be possible to enrol 160 patients WAD II within
12 months in areas with 400,000 inhabitants.
Most sample size calculations involve estimating the
number of observations needed to compare two means by
using Student's t test for independent samples or two pro-
portions by using Pearson's chi-square test. Standard prac-
tice is to determine the sample size that gives an 80%
chance of rejecting the hypothesis of no difference at the
0.05 level of significance.
We have assumed a correlation between baseline meas-
ures and outcome scores of 0.4, based in previous studies
about randomized clinical trial design in whiplash associ-
ated disorders. [43]
A sample of 90 subjects per group provides at least an 80%
probability of detecting an effect of botulinum toxin of
1.5 cm on a 10 cm VAS pain intensity measure and 10%
on the 0–100% NPDI.
In addition, we assumed that the standard deviation (SD)
of pain intensity is 2.5 cm [44-46] and the SD for NPDI is
20% [47-49], and that alpha is 0.05.
Data analysis
The primary outcome measure is the change from base-
line at week 8. The mean change in the Botox (®) group
will be compared to that of the placebo group, and the sta-
tistical significance will be calculated by using the two-
sample t test. Patients will be included in the primary
analysis on the basis of intention-to-treat. Patients who
withdraw prematurely will have week 8 outcomes meas-
ured at the time of withdrawal.
All analyses will be intention-to-treat analyses.
The analytic strategies will be as follows: ordinary least
squares regression models for each continuous outcome
from baseline to follow up assessment: logistic regression,
to estimate the effects of treatment on dichotomous out-
comes and mixed effects linear models, to identify
changes by treatment group over the follow-up.
Age, sex, SF-36 mental score, baseline outcome value,
duration of neck pain will be included in the ordinary
least squares and logistic models. The mixed effects mod-
els include the same covariates except baseline outcome
value. The logistic model includes results with odds ratios
and 95% confidence intervals for each treatment contrast.
Informed consent
All patients will sign the appropriate institutional review
board and ethics review committee approved protocol
specific informed consent prior to any protocol proce-
dures. The consent form will include all relevant informa-
tion from the patient package insert of the product.
Consent will be documented by patient's dated signature
on a consent form along with the dated signatures of the
person conducting the consent discussion.
Efficacy
BTX-A injections are not a curative treatment. BTX-A pro-
vides a temporary paralytic effect and requires repeated
injections to continue the beneficial effects. The duration
of effect is longer with the initial injection and progres-
sively gets shorter with repeated injections for most dys-
tonic disorders. It is not known at this time whether BTX-
A can be readministered indefinitely or if the effectiveness
will wear off over time.
Primary efficacy measure: change in mean monthly pain
and ROM during the 3rd and 6th study month compared to
the pre-trial period and compared with the placebo-
treated group: medications requirements and improve-
ment of symptoms compared with the placebo treated
group. Finally, improved health-related disability com-
pared with placebo-treated group.
Discussion
BTX-A (Botox®) has been found to be safe and effective for
a number of clinical conditions. Presently, BTX-A has
been approved by the Federal Drug Administration.
(FDA) for the treatment of cervical dystonia in adults to
decrease the severity of abnormal head position and neck
pain associated with cervical dystonia, and for treatment
of strabismus and blepharospasm associated with dysto-
nia.
Listed below are clinical applications for which BTX-A is
not approved by the FDA, but where data exists to support
the clinical use of BTX-A:
• Spasmodic torticollis
• Writer's cramp with significant wrist-joint deviation
• Spasmodic dysphoniaBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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• Dynamic contracture in cerebral palsy patients
• Post Stroke Spasticity
• Myofascial pain syndrome
• Chronic low back pain
Following are the clinical conditions where insufficient
data exists to support the clinical use of BTX-A and none
of these are FDA approved indications:
• "Off" painful dystonia in Parkinson's disease patients
• Rigidity in Parkinson's disease patients
• TMJ disorders and Bruxism
• Fixed contracture in cerebral palsy patients
• Spasticity associated with Multiple sclerosis
• Tension headache
• Migraine
• Whiplash associated with neck-pain
• Spasticity associated with Perinatal hypoxia
• Progressive supranuclear palsy
• Cortical basal degeneration
• Extensor hallucis longus dystonia
• Writer's cramp with neutral wrist position
• Essential tremor
• Stenographer's cramp
• Sixth nerve palsy
Botulinum toxin
The strains of Clostridium botulinum produce a group of
the most potent biological toxins that act by preventing
synaptic transmission of acetylcholine across the neu-
romuscular junction. BTX is classified into eight distinct
serologically related neurotoxins, seven of which can
cause paralysis. Three of these types A, B and E are also
associated with epidemic botulism from food poisonings.
The BTX are members of the same class of drugs, and as
such, show important similarities and differences.
Although these toxins are antigenically distinct (i.e. differ-
ent serotypes), they possess similar molecular weights,
and have a similar subunit structure, though different
amino acid sequences. The active toxins have a molecular
weight of approximately 150,000 Daltons and are com-
posed of a heavy chain (100,000 Daltons) that is linked
by a disulfide bond to a light chain (50,000 Daltons) asso-
ciated with a single Zinc atom. BTX exerts its effect at the
neuromuscular junction by inhibiting the release of ace-
tylcholine, and this in turn causes flaccid paralysis. BTX-A
causes chemical denervation by preventing synaptic trans-
mission and effectively weakens the muscle. BTX-A
injected into a muscle binds irreversibly to the nerve,
where it is internalised into the nerve ending, causing
paralysis of the muscle by preventing the release of acetyl-
choline. BTX-A binds rapidly and with high affinity to the
nerve, however, its maximal paralytic effect peaks four to
seven days after the injection. Very little toxin reaches the
systemic circulation. Muscle paralysis is dose dependent
and reversible. Recovery occurs either when new portions
of the nerve, called axonal terminals, sprout and reinner-
vate the muscle or when the original terminal is reacti-
vated. Side effects can occur when too much BTX-A is
injected, when the drug is not contained in an injected
muscle or, very rarely, when an underlying syndrome that
is latent such as Myasthenia Gravis is unmasked by the
injection. Clinical effects of BTX-A injections lasts from
two to six months or more depending on the dose and
condition being treated and repeated treatments are often
necessary to control abnormal muscle functioning. Treat-
ment with BTX-A does not result in a return to normal
muscle functioning since the underlying cause is still
present. BTX-A treatment weakens specific muscles, allow-
ing graded movements, unlike other pharmacological
treatments that weaken all muscles.
Theoretical pharmacological rational for effect in 
whiplash associated disorder
Neck pain after whiplash injuries is a common finding.
Up to 87% of patients with WAD have some degree of
muscle spasm. BTX has demonstrated efficacy in a variety
of conditions associated with muscle spasms. Patients
with WAD have pain-limiting range of motion in the neck
and increased pain with function. In addition, these
patients exhibit marked localized tenderness and often
refer pain to distant sites like active myofascial trigger
points (MTrPs). Exactly how botulinum toxin works has
not been established, but it is presumed that it decreases
active tender points. Unlike standard tender point injec-
tions, BTX produces long-term responses without signifi-
cant adverse events. BTX success in pain management is
attributed to its ability to block acetylcholine from being
released at synapses. The neurotoxin effects are thought to
act only upon motonerve endings while sensory nerve fib-
ers are spared from such effects. Thus, analgesic effects areBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/5
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likely to occur, not as a result of blocking afferents sensory
fibbers at the site of injection, but rather from secondary
effects that may be attributed to muscle paralysis,
improved blood flow, and release of fibers under com-
pression by abnormally contracting muscles. The primary
action may affect alpha and gamma motoneuron function
in the muscle spindles resulting in lower muscle tone.
Although still under extensive study, BTX appears to have
a role in the diagnosis and the treatment of chronic WAD.
As a diagnostic tool, injection of BTX can identify those
cases of whiplash disorder that are primarily myogenous
in nature. As a therapeutic tool, BTX provides a safe, min-
imally invasive, reversible means of treating affected mus-
cles.
Human participation protection
The study protocol and informed conset form will be
approved by the institutional review board of the Povisa
Medical Center and the Regional Commission for Clinical
trails as well as the National Commission of Health Min-
istry.
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